DEFA14A: Dogwood Secures Global SP16 License, NCI Funds CIPN Study

Dogwood Therapeutics obtained an exclusive, royalty-free global license for Serpin Pharma's SP16, a promising drug for chemotherapy-induced peripheral neuropathy, with its Phase 1b study fully funded by the National Cancer Institute.

Summary

• Dogwood Therapeutics entered into an Exclusive Licensing Agreement with Serpin Pharma Inc. and Rejuvenation Labs, Inc. for a royalty-free, sublicensable global license to develop Serpin Pharma's intravenous formulation of SP16.
• SP16 is a first-in-class LRP1 agonist with demonstrated anti-inflammatory and neural repair activity, holding potential to treat chemotherapy-induced peripheral neuropathy (CIPN).
• In consideration for the license, Dogwood issued 382,034 shares of its common stock and 179.1878 shares of Series A-2 Non-Voting Convertible Preferred Stock to Serpin Pharma and Rejuvenation Labs.
• Tungsten Advisors, acting as financial advisor, received 10.8694 shares of Series A-2 Preferred Stock as compensation.
• The Phase 1b CIPN study for SP16 IV is fully funded by the National Cancer Institute, with patient enrollment projected to begin in the first half of 2026.
• Dogwood will assume sole responsibility for regulatory oversight, filings, and approvals for SP16 after the Phase 1b study concludes.
• The Series A-2 Preferred Stock, issued as part of the consideration, is non-voting (except for protective provisions) and will automatically convert into 10,000 shares of common stock per preferred share upon stockholder approval, subject to a 19.9% beneficial ownership limitation.
• Support agreements were executed with Serpin, Tungsten affiliates, and Sealbond Limited, committing them to vote their shares in favor of stockholder proposals required for preferred stock conversion and other related matters.

Sentiment

Score: 9

Explanation: The filing announces a highly strategic and positive development for Dogwood Therapeutics. The acquisition of an exclusive, royalty-free global license for a promising drug candidate (SP16) significantly expands the company's pipeline in a high-unmet-need area. The fact that the Phase 1b study for SP16 is fully funded by the National Cancer Institute is a major de-risking factor and a strong endorsement of the asset's potential. The potential for synergistic action with the existing lead candidate, Halneuron, further enhances the long-term value proposition. While there is some dilution from the all-stock transaction and a need for stockholder approval for preferred conversion, the overall strategic benefits and non-dilutive funding for SP16's early development are overwhelmingly positive.

Positives

• Secured an exclusive, worldwide, royalty-free license for SP16, significantly expanding the company's research pipeline.
• SP16 is a first-in-class LRP1 agonist with dual anti-inflammatory and neural repair activity, offering a novel approach to chemotherapy-induced peripheral neuropathy (CIPN).
• The Phase 1b clinical study for SP16 IV is fully funded by the National Cancer Institute, substantially de-risking early development costs for Dogwood.
• SP16 has the potential for synergistic use with Halneuron, Dogwood's lead candidate, to address a broader range of cancer-related pain and neuropathy symptoms.
• The transaction is structured as an all-stock deal, preserving Dogwood's existing cash reserves for other development activities.
• SP16 preclinical data demonstrates anti-inflammatory and analgesic benefits, as well as neural restorative and repair activity.
• In-vitro assays indicate SP16 does not interfere with the effectiveness of common chemotherapy regimes (platinum, taxane, topoisomerase 1 inhibitor).

Negatives

• The issuance of common and preferred stock as consideration will result in dilution for existing shareholders.
• Stockholder approval is required for the conversion of the Series A-2 Preferred Stock into common stock, introducing a contingency for full integration of the equity.

Risks

• The continued listing of common stock on Nasdaq is subject to various risks.
• The impact of the Licensing Agreement on the price of common stock is uncertain.
• The ability to successfully develop and commercialize SP16 is not guaranteed and involves inherent uncertainties.
• Clinical studies for both SP16 and Halneuron are subject to risks, uncertainties, and assumptions that are difficult to predict.
• Actual results, levels of activity, performance, or achievements may materially differ from forward-looking statements.
• The beneficial ownership limitation on preferred stock conversion could affect the liquidity or voting power of large holders if not adjusted.

Future Outlook

Dogwood Therapeutics plans to file an Investigational New Drug (IND) application for SP16 in Q4 2025, with patient enrollment for the NCI-funded Phase 1b CIPN study projected to begin in the first half of 2026. For its lead candidate, Halneuron, the company expects to file new synthetic IP in Q4 2025, recruit 100 patients in the Phase 2b CINP study by Q4 2025, and release interim data from 90-100 patients in December 2025, with final data for the 200-patient study anticipated in Q2/Q3 2026. The company also expects to hold a special meeting in Q4 2025 for stockholder approval of preferred share conversions.

Management Comments

• "The SP16 in-license aligns with our strategic objective of expanding our research pipeline in an area where Dogwood's pain and neuropathy management research expertise can add value to both the asset increasing our equity value for shareholders." Greg Duncan, Dogwood Therapeutics CEO.
• "The National Cancer Institute's funding of the SP16 IV Phase 1b program obviates the need to use our existing capital in the near-term to advance SP16 into clinical development." Greg Duncan, Dogwood Therapeutics CEO.
• "After reviewing potential partners for this program, we believe Greg Duncan and the Dogwood team is best poised to take SP16 IV for cancer related pain through the clinic to address this major unmet need." Dr. Cohava Gelber, CEO of Serpin Pharma.
• "SP16 IV may have intrinsic potential to deliver adjunctive improvement of non-pain symptoms if utilized with Halneuron, the Company's lead development candidate." Lawrence Steinman, MD, Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford University and Scientific Advisory Board Member of Serpin Pharma.
• "Expanding a biotech company's quality shots on goal is always valued, but doing so with two development candidates that stand on their own merit, with additional potential to be mechanistically synergistic, adds additional value to this exciting worldwide SP16 license." Mike Gendreau, M.D., Ph.D., Dogwood Therapeutics Chief Medical Officer.
• "We intend to explore the potential of SP16, both as a treatment for a multitude of CIPN symptoms, as well as its potential to help with repair and/or restoration of nerve function damaged by chemotherapy." Mike Gendreau, M.D., Ph.D., Dogwood Therapeutics Chief Medical Officer.

Industry Context

The licensing of SP16 positions Dogwood Therapeutics to address a significant unmet medical need in chemotherapy-induced peripheral neuropathy (CIPN), a debilitating condition for which there are currently no approved drugs. This strategic move expands Dogwood's pipeline in pain and neuropathy management, complementing its existing lead candidate, Halneuron, which is in Phase 2b development for chemotherapy-induced neuropathic pain (CINP) and has FDA fast-track designation. The potential for synergistic action between SP16's anti-inflammatory and neural repair properties and Halneuron's analgesic effects could offer a comprehensive treatment approach, enhancing Dogwood's competitive standing in the oncology and pain management markets. The National Cancer Institute's full funding of the SP16 Phase 1b study underscores the high unmet need and the unique potential of this therapeutic approach within the industry.

Comparison to Industry Standards

• There are currently no drugs approved to treat chemotherapy-induced neuropathic pain (CINP) or chemotherapy-induced peripheral neuropathy (CIPN), highlighting a very large commercial opportunity for Dogwood's candidates.
• Halneuron has demonstrated statistically significant and clinically meaningful pain reductions in general cancer pain and CINP in previous Phase 2 studies, indicating competitive efficacy.
• Halneuron has shown no evidence of addiction, euphoria, or tolerance, which is a critical advantage in the pain management industry, especially compared to opioid-based treatments.
• The National Cancer Institute's full funding of the SP16 IV Phase 1b program reflects the uniqueness and extraordinary unmet medical need associated with this debilitating cancer-related condition, suggesting a strong competitive advantage in securing non-dilutive funding for early-stage development.

Corporate Governance

Related Party Transactions

• Tungsten Advisors (through Finalis Securities LLC) acted as financial advisor to Dogwood Therapeutics in connection with the licensing agreement and received 10.8694 shares of Series A-2 Preferred Stock as compensation.

Stakeholder Impact

• Shareholders: Potential for increased equity value due to pipeline expansion and de-risked development, but also immediate dilution from the all-stock issuance. Voting on preferred stock conversion is required.
• Patients: Potential for new, effective treatments for chemotherapy-induced peripheral neuropathy (CIPN) and cancer-related pain, addressing a significant unmet medical need.
• Employees: Potential for expanded research and development opportunities, possibly leading to company growth and increased job stability.
• Serpin Pharma/Rejuvenation Labs: Became significant shareholders in Dogwood Therapeutics and secured a partner for SP16 development, leveraging Dogwood's expertise.

Next Steps

• File a Form S-3 registration statement for the newly issued shares (within 15 days of September 29, 2025).
• Cause the Form S-3 registration statement to be declared effective by the SEC as soon as practicable, but no later than December 1, 2025.
• File an IND for SP16 to advance to Phase 1b safety study (projected Q4 2025).
• Begin patient enrollment in the fully funded SP16 IV Phase 1b CIPN study (projected 1H 2026).
• File new synthetic Halneuron IP to support Phase 3 and commercialization (projected Q4 2025).
• Recruit 100 patients in the Halneuron Phase 2b study (projected Q4 2025).
• Release interim data from 90-100 patients in the Halneuron Phase 2b CINP study (projected December 2025).
• Obtain final data for the 200-patient Halneuron Phase 2b CINP study (projected Q2/Q3 2026).
• Hold a special meeting for stockholder approval of preferred share conversions (contemplated Q4 2025).
• Serpin to transfer relevant IND application related to the System and the Field to Dogwood following conclusion of the Phase 1b study.

Key Dates

Recommendation

The acquisition of an exclusive, royalty-free global license for SP16 represents a highly strategic and transformative move for Dogwood Therapeutics. The drug candidate addresses a critical unmet medical need in chemotherapy-induced peripheral neuropathy (CIPN), a market with no approved treatments. The most compelling aspect is the full funding of the SP16 Phase 1b study by the National Cancer Institute, which significantly de-risks early development and preserves Dogwood's capital. This, combined with the potential for synergistic effects with the company's existing lead candidate, Halneuron, creates a robust and diversified pipeline in pain and neuropathy management. While there is some dilution from the all-stock transaction, the long-term value creation potential from expanding 'shots on goal' with non-dilutive funding for a key asset makes this a strong buy opportunity for investors looking for growth in the biotechnology sector.

Keywords

Biotechnology, Pharmaceuticals, Pain Management, Neuropathy, Cancer Treatment, SP16, Halneuron, LRP1 Agonist, NaV1.7 Inhibitor, Clinical Trials, SEC Filing, Licensing Agreement, Oncology, Drug Development, Chemotherapy-Induced Peripheral Neuropathy, CIPN, CINP, Dogwood Therapeutics, Serpin Pharma, National Cancer Institute